Chi’s Outreach Survey results released, 2/17
February 2017—Chi Solutions, an Accumen company, has released a research report that includes the results of its 15th annual comprehensive Outreach Survey, conducted in early 2016.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
CALR mutation assay for MPN diagnosis, 2/17
February 2017—Qiagen announced the European launch of its CE-IVD marked calreticulin mutation assay to aid in establishing the diagnosis of myeloproliferative neoplasms. The ipsogen CALR RGQ PCR kit is intended for the detection of CALR mutations in genomic DNA from subjects suspected of myeloproliferative neoplasms. It enables identification of the two major CALR mutations, type 1 and type 2, and detects additional mutations in the CALR exon 9 region.
CE mark for handheld blood testing device , 2/17
February 2017—Abbott’s i-Stat Alinity System, a handheld blood testing platform, received CE marking and is for sale in Europe and other countries that recognize the CE mark. The portable device can perform and analyze a large menu of blood tests on a single device, ranging from blood chemistries to cardiac markers, using two to three drops of a person’s blood.
Test IDs patients who may benefit from olaparib, 2/17
February 2017—Myriad Genetics announced that its BRACAnalysis CDx test accurately identified patients who may benefit from treatment with olaparib. The test was included in the SOLO2 study as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca.
Horizon, CareDx enter into OEM agreement, 2/17
February 2017—Horizon Discovery Group has entered into an original equipment manufacturer agreement with CareDx. Under the terms of the new agreement, Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for monitoring transplanted organ rejection.
FDA clears strep assay , 2/17
February 2017—Quidel has received 510(k) clearance from the Food and Drug Administration to market its Solana Strep Complete Assay for the rapid and qualitative detection and differentiation of Streptococcus pyogenes (group A beta-hemolytic streptococcus) and Streptococcus dysgalactiae (pyogenic group C and G beta-hemolytic streptococcus) nucleic acids isolated from throat swab specimens obtained from symptomatic patients.
Rapid test for emergency evaluation of sepsis, 2/17
February 2017—Nanomix released a rapid diagnostic test panel designed to quickly evaluate patients affected by sepsis and that runs on Nanomix eLab, the company’s handheld diagnostic system. Designed for emergency medical and other point-of-care needs, the test uses a single patient blood, plasma, or serum sample to provide actionable results within 10 minutes.
Streck adds Makler to sperm count assays, 2/17
February 2017—Streck’s Sperm-Chex and Sperm-Chex Post VC, both with stabilized sperm cells, are now assayed for the Makler Counting Chamber. Sperm-Chex has two clinically significant levels of control to simulate the sperm cell concentration that technologists encounter in patient samples. It has the same chamber loading and optical characteristics as a patient sample. Sperm-Chex verifies the sperm analysis process and tests the technologist’s proficiency in sperm cell quantification and qualification.
Visiopharm acquires LRI Imaging, 2/17
February 2017—Visiopharm A/S, headquartered in Hørsholm, Denmark, announced its acquisition of LRI Imaging AB, based in Sweden.
Antigens and antibodies for assay development, 2/17
February 2017—Meridian Life Science released a new brochure on its best performing tropical and vector-borne antigens and antibodies, including its new Zika reagents. Important troubleshooting tips are included for reducing cross-reactivity in flavivirus assays and increasing IgM detection sensitivity.